Why I Still Don't Think Amgen Is A Buy

Amgen (AMGN) reported robust Q2 2025 financial results, surpassing analyst expectations with a 9.4% revenue increase to $9.179 billion and a 92.0% surge in diluted EPS, prompting an upward revision of its full-year guidance. The company also unveiled positive Phase II data for its promising obesity drug MariTide, which is now advancing into multiple Phase III trials, signaling significant growth potential. However, the firm continues to navigate a substantial debt burden from the Horizon acquisition, leading to the suspension of share buybacks, despite ongoing efforts to improve its balance sheet. This mixed financial picture, combining operational strength and pipeline promise with lingering debt concerns, positions Amgen as a 'Hold' with a positive outlook.

Analysis

Amgen Inc. delivered a strong second quarter for fiscal 2025, beating analyst expectations with revenue growing 9.4% year-over-year to $9.179 billion and diluted earnings per share surging 92.0% to $2.65. This performance, driven by significant growth in products like Repatha (+31%) and Uplizna (+91%) which more than compensated for the 34% decline in Enbrel sales, prompted management to raise its full-year 2025 guidance. The company’s growth outlook is further supported by positive updates on its key pipeline asset, MariTide, an obesity treatment now entering four Phase III studies after demonstrating approximately 20% weight loss at 52 weeks. However, these positive operational and clinical developments are tempered by significant financial constraints. The balance sheet remains highly leveraged with a debt-to-equity ratio of 7.57 following the Horizon Therapeutics acquisition, and free cash flow declined 13.6% year-over-year in the quarter. Consequently, Amgen has suspended its significant share buyback program, a historical driver of EPS growth, capping it at $500 million for the year to prioritize debt reduction.

Key Decisions for Investors

• Given the strong Q2 earnings beat, raised full-year guidance, and promising clinical data for the obesity drug MariTide, investors could view the current operational momentum as a key positive catalyst for the stock.
• Investors must closely monitor the company's deleveraging progress and free cash flow generation, as the high debt level remains a significant overhang that has forced the suspension of its historically value-accretive share buyback program.
• It is critical to track developments in the broader obesity drug market, including signs of market saturation mentioned in Novo Nordisk's guidance, as the ultimate success and valuation of MariTide will be heavily dependent on these external competitive and market-size dynamics.